Biolidics (SGX:8YY) loss for the third quarter of the year stood at SG$420,000, down nearly 30% year over year from SG$596,000, a filing with the Singapore Exchange said on Friday.
Loss per share came in at SG$0.0006 from SG$0.0007 in the year-ago period.
The diagnostic solutions provider's revenue was up 7% year over year to SG$15,000 from SG$14,000, mainly due to a slight increase in revenue from sales of CTChip FR1 biochip.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.